Axa S.A. Chinook Therapeutics, Inc. Transaction History

Axa S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $166,188 - $248,160	-13,200 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$12.02 - $16.69 $158,664 - $220,308	13,200 New	13,200 $215,000
Q1 2022 May 13, 2022	SELL	$12.02 - $16.69 $70,918 - $98,471	-5,900 Reduced 30.89%	13,200 $216,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $47,036 - $74,051	-4,400 Reduced 18.72%	19,100 $312,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $270,250 - $349,210	23,500 New	23,500 $300,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.